lidocaine
Commercial- Indications
- Post-herpetic neuralgia
Company intelligence / Profile preview
Stason Pharmaceuticals has a robust portfolio of generic and branded drugs with a focus on oncology and orphan indications. The company has commercialized multiple products in the US generics market since 1994. It also develops proprietary compounds for oncology and other therapeutic areas. Its pipeline includes both approved drugs such as mercaptopurine for leukemia and investigational assets like NI-03 for pancreatitis currently in Phase 2 trials
4 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Stason Pharmaceuticals.